Xlife Sciences AG (SIX: XLS) announced that shareholders approved all proposals presented at the company’s Annual General Meeting, where 3,134,367 voting shares, representing 54.3% of the total share capital, were represented. Chairman David L. Deck said the company strengthened its portfolio during the past year and highlighted the Nasdaq listing of portfolio company Veraxa Biotech (NASDAQ: VRXA) and the planned Landsteiner Scientific platform as key milestones supporting the next phase of growth.
The company also emphasized the strategic importance of the planned Landsteiner Scientific platform, which is intended to accelerate the identification and development of novel therapeutic approaches while improving global market access for Xlife Sciences’ portfolio companies. Management said the platform will integrate academic research with commercial development and serve as a cornerstone of the company’s future innovation pipeline, while also outlining upcoming capital markets activities.
Xlife Sciences operates as an incubator and accelerator focused on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector. The company targets high unmet medical needs by bridging research and development to healthcare markets. It selects projects in four areas: technological platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health.
The approval of all proposals at the Annual General Meeting reflects shareholder confidence in Xlife Sciences’ strategic direction. The successful Nasdaq listing of Veraxa Biotech represents a significant validation of the company’s ability to bring portfolio companies to public markets, while the Landsteiner Scientific platform is expected to enhance the pipeline of novel therapies and improve commercialization efforts globally.
Xlife Sciences continues to focus on creating value from academic research, aiming to provide solutions for unmet medical needs and improve quality of life. The company’s approach involves taking carefully selected projects to the next stage of development and participating in their subsequent performance.
